Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2003;34:2387-2391
Published online before print August 28, 2003, doi: 10.1161/01.STR.0000088642.07691.15
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/10/2387    most recent
01.STR.0000088642.07691.15v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santamaría, A.
Right arrow Articles by Fontcuberta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santamaría, A.
Right arrow Articles by Fontcuberta, J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Arterial thrombosis
Right arrow Thrombosis risk factors
Right arrow Acute Cerebral Infarction

(Stroke. 2003;34:2387.)
© 2003 American Heart Association, Inc.


Original Contributions

Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels

A. Santamaría, MD; A. Oliver, MD; M. Borrell, PhD; J. Mateo, MD, PhD; R. Belvis, MD; J. Martí-Fábregas, MD, PhD; R. Ortín;; I. Tirado, PharmD; J.C. Souto, MD, PhD J. Fontcuberta, MD, PhD

From the Hemostasis and Thrombosis Unit, Hematology Department (A.S., M.B., J.M., R.O., I.T., J.C.S., J.F.), Neurology Department, (R.B., J.M.-F.), and Fundación Puigvert (A.O.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Correspondence to Dr A. Santamaría, Department of Hematology, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni Ma Claret, 167, 08025-Barcelona, Spain. E-mail msantamaria{at}hsp.santpau.es

Background and Purpose— Recently, a novel procarboxypeptidase B–like proenzyme, called thrombin-activatable fibrinolysis inhibitor (TAFI), has been described. It plays an important role in the delicate balance between coagulation and fibrinolysis. TAFI leads to potent inhibition of tissue plasminogen activator–induced fibrinolysis. The relevance of TAFI in thromboembolic disease is unclear. We have investigated the risk of ischemic stroke (IS) in relation to plasma levels of functional TAFI.

Methods— In a case-control study, we enrolled 264 individuals; 114 had IS, and 150 were recruited as controls who were age and sex matched and had no history of arterial disease. The individuals supplied information on their personal and family histories of cardiovascular diseases and conventional cardiovascular risk factors. Functional TAFI assays were performed by use of a method based on the activation of TAFI with thrombin-thrombomodulin and the measure of the TAFI activity generated. Other hemostatic parameters assayed were factor VIIIc, anti-phospholipid antibodies,fibrinogen, factor V Leiden, and the prothrombin gene G20210A mutations (PT20210A).

Results— Functional TAFI levels were significantly higher in patients with IS (113.7±25%; range, 57% to 209%) than in controls (102.6±19%). The odds ratio for IS in patients with functional TAFI levels >120% was 5.7 (95% confidence interval, 2.3 to 14.1).

Conclusions— We found that functional TAFI levels in plasma (>120%) increased the risk of IS {approx}6-fold. Further studies should elucidate the physiological role of TAFI in arterial disease and possibly provide clues to therapeutic approaches.


Key Words: fibrinolysis • stroke, ischemic • thrombosis




This article has been cited by other articles:


Home page
BloodHome page
O. Salomon, D. M. Steinberg, N. Koren-Morag, D. Tanne, and U. Seligsohn
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
Blood, April 15, 2008; 111(8): 4113 - 4117.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P. J. Declerck, and C. Jern
Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 955 - 962.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J.-M. Olivot, J. Labreuche, M. Aiach, P. Amarenco, and for the GENIC Investigators
Soluble Thrombomodulin and Brain Infarction: Case-Control and Prospective Study
Stroke, August 1, 2004; 35(8): 1946 - 1951.
[Abstract] [Full Text] [PDF]